
Join to View Full Profile
245 1st StSte 16Cambridge, MA 02142
Phone+1 617-301-7076
Fax+1 617-301-7030
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 3 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Theresa Podrebarac, MD is a rheumatologist in Cambridge, Massachusetts. She is currently licensed to practice medicine in Massachusetts.
Education & Training
University of Western OntarioClass of 1990
Certifications & Licensure
MA State Medical License 1996 - 2015
Awards, Honors, & Recognition
- Fellow (FACR) American College of Rheumatology
Clinical Trials
- Multicenter Study to Evaluate CRx-102 vs. Each of Its Components to Treat Active Rheumatoid Arthritis Start of enrollment: 2007 Oct 01
- A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB) Start of enrollment: 2019 Jan 09
Publications & Presentations
PubMed
- 123 citationsCadherin-11 Provides Specific Cellular Adhesion between Fibroblast-like SynoviocytesXavier Valencia, Jonathan M.G. Higgins, Hans P. Kiener, David Lee, Theresa Podrebarac
The Journal of Experimental Medicine. 2004-12-20 - 400 citationsMurine CD1d-Restricted T Cell Recognition of Cellular LipidsJenny E. Gumperz, Christopher L. Roy, Anna Makowska, Deirdre Lum, Masahiko Sugita
Immunity. 2000-02-01 - 160 citationsDiverse TCRs Recognize Murine CD1Samuel M. Behar, Theresa Podrebarac, Chad J. Roy, Chyung Ru Wang, Michael B. Brenner
Journal of Immunology. 1999-01-01
Press Mentions
Horizon Therapeutics Plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus ErythematosusJanuary 4th, 2023
Data Presented from the MIRROR Randomized Controlled Trial Demonstrate KRYSTEXXA® (Pegloticase Injection) plus Methotrexate Resulted in Significant Improvement in Efficacy and Safety (Infusion Reactions) Compared to KRYSTEXXA MonotherapyJune 1st, 2022
First IPF Patient Enrolled in Phase 2b Trial of Oral HZN-825January 25th, 2022- Join now to see all
Professional Memberships
- Fellow









